BCMA: Predicting Outcomes and Monitoring MM and CLL

Outcomes for patients with multiple myeloma who are TCE and BCMA-exposed are poorПодробнее

The utility of MRD for predicting treatment outcomes in patients with CLLПодробнее

Predicting Response to Therapy in CLLПодробнее

The role of measuring MRD in CLLПодробнее

Telomere dysfunction to predict clinical outcomes in CLLПодробнее

Minimal residual disease (MRD) in CLL: Is it clinically relevant?Подробнее

Improving outcomes of BCMA-targeting ADCs in multiple myelomaПодробнее

Role of BCMA in Predicting Outcomes and Monitoring MM and CLLПодробнее

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 ResultsПодробнее

Outcomes of BCMA-exposed vs BCMA-naïve patients with R/R multiple myelomaПодробнее

Mutation Status Throughout the CLL Clinical CourseПодробнее

Analysis of outcomes of younger CLL patientsПодробнее

The impact of MRD & genetics on outcomes to time-limited combinations in patients with CLLПодробнее

Unanswered questions in frontline CLL treatmentПодробнее

BCMA: A new biomarker for multiple myelomaПодробнее

Exciting results from CARTITUDE-1: anti-BCMA CAR-T for MMПодробнее

The role of MRD as a prognostic & predictive biomarker in CLLПодробнее

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)Подробнее